APA (7th ed.) Citation

Lara, M. S., Gubens, M. A., Bacaltos, B., Daran, L., Lim, S. L., Li, T., . . . Blakely, C. M. (2022). Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC. JTO Clinical and Research Reports, 3(12), . https://doi.org/10.1016/j.jtocrr.2022.100436

Chicago Style (17th ed.) Citation

Lara, Matthew S., et al. "Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC." JTO Clinical and Research Reports 3, no. 12 (2022). https://doi.org/10.1016/j.jtocrr.2022.100436.

MLA (8th ed.) Citation

Lara, Matthew S., et al. "Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC." JTO Clinical and Research Reports, vol. 3, no. 12, 2022, https://doi.org/10.1016/j.jtocrr.2022.100436.

Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.